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A b s t r A c t
bAcKGrOUND: Transcatheter closure of secundum atrial septal defect (ASD) is 
nowadays widely practiced and has replaced surgical ASD closure in many centers. 
Improvements in design have made the closure devices retrievable, and reduction in 
the size of the introduction systems allows interventional treatment even in young 
patients. In this paper we present our experience with the Amplatzer septal occluder 
device in patients with ASD. 
PAtIENts AND MEtHODs: Between October 2002 and February 2006, 206 consecu-
tive patients with a significant ASD, demonstrated by initial transthoracic echocardi-
ography (TTE), were considered for transcatheter closure with the Amplatzer septal 
occluder. A total of 156 patients underwent cardiac catheterization, and 140 patients 
had successful transcatheter ASD closure. Routine examination before catheteriza-
tion included a standard ECG, a chest x ray, blood tests and TTE. The initial TTE 
showed the location of the ASD, its septal rim, and its diameter and also helped to 
measure the length of the interatrial septum in the four-chamber view. These measure-
ments were used to assess the feasibility of transcatheter closure with the Amplatzer 
device. The “stretched” diameter of the ASD, determined by a balloon sizing catheter, 
was used to select the diameter of the waist of the device. The size of the selected de-
vice was 1 to 2 mm larger than the stretched diameter of the defect. Transesophageal 
echocardiography was used to monitor the implantation procedure.
rEsULts: The Amplatzer device was finally employed in 140 patients for percutane-
ous closure of ASD. The age of patients ranged between 5.3 and 70 years, median 
21.9 years. Procedure time ranged between 25 and 240 minutes, median 60 minutes; 
fluoroscopy time ranged between 3.5 and 45 minutes, median 12 minutes. The size of 
the selected device ranged between 6-40 mm. Two devices were implanted in two pa-
tients. Serious procedure related complications (embolization and perforation of the 
left atrial wall) occurred in two cases. At follow up (10 days to 3.4 years, median 2.3 
years) complete closure was documented in 97% of this patient group. Unrecognized 
during implantation, but detected after release, small additional defect with trivial re-
sidual shunt was documented in 4 patients. A young critically ill patient, cyanotic due 
to right-to-left shunt, with complex congenital heart disease developed a brain abscess 
three months after implantation. 
cONcLUsION: Percutaneous ASD closure with use of the Amplatzer device in this 
cohort of 140 patients was highly successful with a low complication rate.
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I N t r O D U c t I O N
The first nonoperative closure of atrial secundum defect 
(ASD) was performed by Noel L. Mills and Terry D. King 
in a 17-year old female patient on April 8, 19751,2. In the fol-
lowing years (1983) Rashkind developed a Clamshell device3. 
There was little interest in this clinical field and the trials with 
the “Clamshell Device” had been discontinued because of 
arm fractures. From the late 1980s until the mid 1990s E. B. 
Sideris (“Buttoned Device”)4 and Babic5 (“ASDOS”) kept the 
ideas of King & Mills alive while G.S. Das developed the first 
self-centering device (“Angel Wings”)5-7. Clinical trials with 
ASDOS and Angel Wings have stopped because of complicated 
technology and risk of perforation. Since the pioneering works 
of King & Mills marked improvements in devices and delivery 
systems have been achieved.
Device ASD closure is now widely practiced and has replaced 
surgical ASD closure in many centers. Improvements in design 
have made the devices retrievable, and reduction in the size of 
the introduction systems allows interventional treatment even 
in young patients. Different types of device are in widespread 
use, and new devices are being introduced. While the patch 
type occlusion device—represented by the CardioSeal, or its 
modification, the StarFlex8,9 occluder (NMT Medical) and the 
Helex-device7 (Gore) mimics surgery by placing a patch over 
the ASD, the self centering Amplatzer septal occluder6,8, (AGA 
Medical Corporation) offers a different approach by stenting 
the interatrial communication. This unique technique makes 
it possible to close even up to 40 mm large defects, while the 
inability to close such large defects remains a limitation of the 
patch type devices.
Since the first clinical trials with the Amplatzer septal 
occluder in 1995 and 1997, there have been many reports of 
excellent early follow up results after ASD closure with the 
Amplatzer occluder6-12. We now report our own clinical expe-
rience and short-midterm results with this device in patients 
who have presented with ASDs in our center.
P A t I E N t s - M E t H O D s
Between October 2002 and February 2006, 206 consecu-
tive patients with a significant ASD, demonstrated by initial 
transthoracic echocardiography (TTE), were considered for 
transcatheter closure with the Amplatzer septal occluder. A 
total of 156 patients underwent cardiac catheterization, and 
140 patients had successful transcatheter ASD closure with 
the Amplatzer device.
Routine examination before catheterization included a 
standard ECG, a chest x ray, blood tests and TTE (Figure 
3A). Magnetic resonance imaging (MRI) (Figure 3B), trans-
esophageal echocardiography (TEE), Valsalva maneuver and 
contrast injections were performed in selected cases.
We followed the manufacturer’s recommendation for 
echocardiographic exclusion criteria if the patient presented 
in TTE or TEE a distance of less than 5 mm from the rim of 
the defect to the atrioventricular valves, the coronary sinus, 
or the right upper pulmonary vein. After ASD closure the 
patients remained in the hospital for one night, and received 
heparin (partial thromboplastin time ≥50-60 seconds) for 14-
18 hours, followed by aspirin 2-3 mg/kg/d or and clopidogrel 
75 mg/d for six months. In the stroke group and in cases with 
coagulation disorders warfarin or acenocoumarol were given 
FIGUrE 1. Patient age distribution.
FIGUrE 2. Gender distribution: 49 were male (35%) and 91 
female (65%).
FIGUrE 3. The ASD as depicted by TTE (A), and MRI (B) in 
two candidates for interventional therapy. Volume overload-large 
right atrium and ventricle, central ASD with adequate rims.
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for six to twelve months. Before discharge an ECG, a biplane 
chest x ray, and a TTE examination were performed. Follow 
up examinations including ECG were scheduled at 1, 3, 12, 
24, and 48 months after the procedure. The 3 and 12 month 
follow-up examination also included a 24 hour Holter ECG 
recording. In order to study the right ventricular-remodeling, 
MRI studies were performed in 32 patient 3-12 months before 
and after transcatheter closure.
The initial TTE (Figure 4) showed the location of the ASD, 
its septal rim, and its diameter and also enabled us to measure 
the length of the interatrial septum in the four chamber view. 
These measurements were used to assess the feasibility of 
transcatheter closure with the Amplatzer septal occluder. The 
Amplatzer septal occluder is a self expanding, self centering, 
and repositionable double disc device constructed of a mesh 
of 72 nitinol wires. A 3-4 mm short cylindrical waist connects 
the two round discs. Basically, the Amplatzer septal occluder 
stretches and stents the ASD. Thus the diameter of the waist 
has to correspond to the so called “stretched” diameter of the 
ASD, determined by a balloon sizing catheter. Additionally, 
polyester fibers are sewn into the device promoting thrombosis 
and complete defect occlusion. Twenty seven different sizes 
with waist diameters from 4-40 mm are available. For devices 
between 4-10 mm, the left atrial disc is 12 mm larger than the 
waist and the right atrial disc is 8 mm larger. For bigger devices 
the left atrial disc is either 14 mm larger than the waist (waist 
diameter 11-30 mm) or 16 mm larger than the waist (waist 
diameter 32-40 mm).
For transvenous implantation of the Amplatzer occluder, 
the manufacturer provides a loader, a delivery cable, and a 6-12 
French long sheath. Before loading the device into the long 
sheath it is connected to the delivery cable by a microscrew 
fixed to the right atrial disc. In the catheterization laboratory 
a biplane transesophageal echocardiogram (TEE) was done 
under general anesthesia (in all except one) to evaluate the size 
and location of the defect and its margins. Vascular access was 
obtained from the femoral vein, and heparin (100 IU/kg max 
9000 IU, ACT ≥250), and antibiotics (cefazolin) were given; 
two cases with coagulation disorders received danaparoid 
sodium (Orgaran). After making a complete haemodynamic 
evaluation, an anomalous pulmonary vein connection was 
excluded by angiocardiography in the pulmonary artery. The 
“stretched” diameter of the ASD (Figure 5A, 5B and 5C, 5D, 
5E: 2 defects, 2 balloons) was measured using a Numed or 
Amplatzer sizing balloon. A device with a waist diameter similar 
to, or in large defects up to 2 mm bigger than, the stretched 
ASD diameter was chosen. After introducing the long sheath 
over the exchange guide wire into the left upper pulmonary 
vein, the device was inserted and deployed under fluoroscopic 
and TEE guidance, as described in previous publications. A 
secure and stable position of the occluder within the defect 
was checked by a push-pull maneuver (Minnesota wiggle). The 
device and adjacent structures were then examined by TEE 
to ensure that there was no encroachment of the device on 
the atrioventricular valves or the right pulmonary veins. After 
releasing the device from the cable by unscrewing it (Figure 7), 
a final TEE examination was undertaken to demonstrate the 
position of the device and any residual shunting (Figure 8).
FIGUrE 4. TEE with the location of the ASD, its septal rim, and 
its diameter The ASD and the rims must be exactly measured. Only 
patients with a distance of more than 5 mm (rim) of the defect 
to the superior vena cava, atrioventricular valves, the coronary 
sinus, or the right upper lobe pulmonary vein are candidates for 
interventional treatment. Device closure of inferior and anterior 
defects with rims <5 mm or oversized devices could compromise 
the mitral valve or obstruct the SVC, IVC or the pulmonary vein. 
ASD= atrial septal defect; IVC= inferior vena cava; SVC= 
superior vena cava.
FIGUrE 5. ASD sizing procedure: The waist of the balloons, A: 
39 mm and B: 10mm respectively, clearly indicates the “stretched” 
diameter of the atrial septal defects. C, D, E:11-year-old patient 
with two large defects. The waists of the balloons are 16 mm and 
26 mm respectively.
40
HOSPITAL CHRONICLES 3(1), 2008
r E s U L t s
Between October 2002 and February 2006, 156 patients 
underwent cardiac catheterization, and 140 patients had suc-
cessful transcatheter ASD closure with the Amplatzer device. 
Their ages ranged from 5.3 to 70 years (median 21.9 years), 49, 
35%, were male, 91, 65% female (Figure 1and 2 for age and 
gender distribution). The majority (85%) of the patient group 
showed a simple, single centrally located fossa ovalis ASD on 
echocardiographic examination, while 15% of the cases had 
multiple or fenestrated defects, an additional septal aneurysm, 
inferior extension of the defect towards the atrioventricular 
valves or coronary sinus. Nine patients suffered from stroke. 
One patient had a significant residual ASD after previous 
CardioSeal implantation, two devices were implanted in two 
patients, one during the same session.
On TEE, the maximum defect diameter varied between 
4-38 mm, while the balloon stretched diameter (Figure 5) 
varied between 6.5-40 mm. Implanted devices had a waist 
diameter similar to or slightly larger than the stretched di-
ameter implanted, ranging between 6-40 mm (Figure 6). The 
procedure time varied between 45-175 minutes (median 60 
minutes) and the fluoroscopy time between 3.5-65 minutes 
(median 12 minutes), with a tendency to shorter procedural 
and screening times after the initial learning curve. In 55% 
of the patients with an ASD, large devices of 20-40 mm were 
employed and devices <10 mm were used in only 4 patient. 
Two 40 mm devices were implanted.
Nine of 10 patients with multiple or fenestrated defects 
were treated with a single device, while in one patient two 
devices were implanted simultaneously through separate 
delivery systems. Defects with an additional septal aneurysm 
were successfully closed by catching the aneurysm during the 
process of configuring the right atrial disc (or using the cribi-
form occluder in two cases), resulting in a firm compression 
of the aneurysm towards the atrial septum.
At the time of cardiac catheterization, nine patients were 
excluded after TEE examination, as follows: inferior-posterior 
defects and no rim near the orifice of the inferior caval vein, 
defects that were very near the coronary sinus, large defect that 
was near the-entrance of the superior caval vein, with only a 
small rim towards the right pulmonary veins, two symptomatic 
FIGUrE 6. Occluder diameter: 55% of patients with an ASD were 
closed with large devices of 20-40 mm, 42% with devices 10-20 
mm and only 3% with devices <10 mm.
FIGUrE 7. Lateral view of an implanted Amplatzer septal occluder 
(16 mm) during and directly after implantation.
FIGUrE 8. TEE after implantation. The device was inserted 
and deployed under fluoroscopic and TEE guidance. Occluder 
and adjacent structures were then examined to ensure that there 
was no encroachment on the atrioventricular valves or the right 
pulmonary veins.
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children had a defect diameter of more than 36 mm on TEE 
and interatrial septum length of only 46 mm.
Seven further patients were excluded after initial angiog-
raphy, hemodynamic evaluation, balloon sizing of the defect, 
or trial of device placement. Three of these showed drainage 
of the right pulmonary veins into the superior cava vein. One 
symptomatic adult had additional coronary disease. After 
balloon sizing four patients were excluded; three of these had 
large inferior-posterior defects with a stretched diameter of 
between 26 mm and more than 36 mm and an insufficient margin 
towards the inferior caval vein. Despite repeated trials, device 
placement failed in three cases because of insufficient inferior 
margins (1) or large defects with a floppy septum (2).
On color flow Doppler, residual shunting—including foam-
ing through the wire mesh of the device—was seen in about 80% 
of cases directly after implantation. By the time of discharge, 
24 hours after ASD closure, the rate of residual leakage had 
decreased to 15%. During further follow up examinations (10 
days to 3.4 years, median 2.3 years) the complete closure rate 
has reached 97-98%. A trivial residual shunt is still present 
in 4 patients. 2/4 patients had unrecognized small additional 
defects during initial TTE and implantation. The third and 
fourth patient of this subgroup had small defects near the 
superior and inferior vena cava respectively.
After transcatheter closure of the interatrial communication 
in adults a reduction of migraine or headache was observed. 
In this small group of patients (retrospectively analyzed) mi-
graine disappeared completely in 60%, while 40% described 
improvement in symptoms.
There were 3 major procedure related complications at 
our institution. The first was an embolization in a patient with 
small inferior rim directly after release. In this case the device 
embolized just above the mitral valve. Although the child was 
stable and asymptomatic device transcatheter retrieval was not 
attempted. The device was retrieved surgically and the ASD 
closed by patch. The second procedure related complication 
was a perforation of the left atrial posterior wall with the 
extra stiff madrain which led to 5 mm pericardial effusion. 
The procedure was stopped; there were no sequelae of this 
event. A significant event occurred 3 months after a success-
ful and uneventful closure of a fenestrated Fontan with an 
Amplatzer occluder in a young cyanotic patient with complex 
congenital heart disease. This 8-year old girl developed fever 
and headache. Computed tomography showed a brain abscess. 
On TTE no unusual finding, thrombus formation or residual 
shunt were seen. After operation and antibiotic therapy for 
4 weeks, patient’s symptoms completely resolved without any 
neurological sequelae (this event confirms our recommendation 
of life long observation after device implantation).
Relevant cardiac dysrhythmias associated with transcatheter 
closure occurred in one case. A 38-year old man developed 
recurrent atrial flutter three months after uncomplicated ASD 
closure with a 36 mm occluder. In this patient long term main-
tenance of sinus rhythm was achieved first with propafenone. 
Six months later the patient decided to stop his medication. 
Recurrent atrial flutter led us to plan and perform ablation 
of the right circuit. It was not necessary to study the left atrial 
wall or the pulmonary vein region. No patient complained 
about amaurosis fugax or blurred vision after the procedure. 
No other early or late complications such as pericardial ef-
fusion, compromise of intracardiac structures, late device 
embolization, cerebral embolism or endocarditis-occurred 
during follow up.
D I s c U s s I O N
The ease of implantation and the superior success rate of 
ASD closure12 with the Amplatzer septal occluder has led to 
the widespread employment of transcatheter occlusion of ASD 
and has replaced routine surgical closure in many centers8,10,12. 
There is no doubt that this success rate is a result of the design 
of the Amplatzer occluder, which is completely different from 
the patch type systems. The most important aspect is that the 
device’s waist between the left and right retention discs is a 
stent, resulting in self-centering within the defect. Thus, the 
Amplatzer occluder requires only a small rim around the de-
fect for firm cross clamping by the retention discs. The unique 
design, using a nitinol mesh, overcomes many of the limita-
tions of other ASD occlusion devices. Although large delivery 
systems up to 12 French are necessary, the Amplatzer septal 
occluder is retrievable without damaging the device, the device 
is self-centering, and occluders large enough to close defects 
of up to 40 mm in diameter are available. Other devices can 
only close defects of up to 20 mm diameter, which excludes 
many patients with larger defects.
TTE and TEE have proved to be very important tools for 
the exact anatomical delineation of the defect within the atrial 
septum9,11-13. As it is difficult to examine defects in older patients 
using TTE, inspection of the exact nature of the septal rim 
near other cardiac structures like the atrioventricular valves, 
the right pulmonary veins, or the inferior caval vein must be 
carried out with TEE before catheterization. Defects near the 
entrance of the inferior caval vein, should easily be identified 
by TTE in the pediatric age group.
The manufacturer’s recommended exclusion criterion is 
an ASD with a rim to the atrioventricular valves of less than 5 
mm6,8,10,11. Device closure of these inferior and anterior defects 
could compromise the mitral valve. None of our patients with 
a rim of <6 mm developed mitral regurgitation. Similarly, the 
device can obstruct the orifice of the right pulmonary veins in 
rare cases with a more superior and posterior defect location; 
this did not happen in our patients8,11. The possibility of the 
retention discs impinging on sensitive structures is particularly 
pertinent when dealing with small children or using large or 
oversized devices8,11,12. An additional consideration is the 
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length of the interatrial septum, which should be sufficient to 
accommodate the device13.
TEE is also very important to ensure the correct positioning 
of the device before and after its release8,11,13. This is critical 
in the closure of large defects because the left atrial retention 
disc in bigger devices is relatively small in relation to the waist 
diameter. Because of this, its cranial portion tends to slip 
through the defect, and this may result in early or even late 
embolization of the device13,14. Furthermore, TEE is useful 
in directing the catheter through the largest communication 
in cases of multiple ASDs, and helps to reduce the screening 
time significantly8,12,13. It has even been suggested that ASD 
closure with the Amplatzer occluder can be carried out under 
TEE guidance alone13,15.
Cobra head malformation of the Amplatzer septal oc-
cluder is sometimes difficult to overcome and may prolong the 
procedure8,15. While it occurred more often in the past with 
the first generation of Amplatzer devices, it still may happen, 
particularly if there is not enough space for the configuration 
of the left or right atrial disc within the left or right atrium in 
a small patient. This can cause twisting of the occluder during 
deployment owing to the leading edge of the device catching 
on the atrial free wall or the appendage.
A point of criticism of the Amplatzer septal occluder is 
that it sometimes appears bulky after implantation. This may 
be the case if, owing to inaccurate balloon sizing, a device 
with too large a stent is implanted. “Mushrooming” of the 
retention discs can then occur15. This is more likely when the 
stent is compressed so that the waist measured on fluoroscopy 
is more than 4 mm smaller than the nominal diameter of the 
stent8,11-13,15. Inaccurate balloon sizing is now rare owing to the 
introduction of new static sizing balloons; overestimation of 
the defects mushrooming has become rare. Inaccurate sizing 
of the ASD is not the only cause of malformation of the im-
planted occluder; it could also happen if the diameter of the 
retention discs exceeds the length of the interatrial septum11,14. 
To avoid such a deformation and any potential obstruction 
of cardiac structures, this experience led us to be making an 
initial assessment of the interatrial septal length from the four 
chamber view on TTE as an important body weight dependent 
variable. In cases of large ASDs the septal length should not be 
exceeded by the diameter of the left disc occluder. In addition 
to echocardiographic follow up studies, 32 patients also had an 
MRI study, which showed no evidence of any device related 
obstruction. From this limited experience, we conclude that 
MRI, in addition to echocardiography, will allow non-invasive 
follow up examination and probably has the potential to replace 
x ray for ASD closure in the future16. In the future this method 
may be used also as an indicator of endothelialization of the 
device and it could be interpreted as a potential advantage 
that protects the integrity of the occluder8,16.
The high percentage of previously reported residual leaks, 
which were up to 53% with the first generation of patch type 
devices has improved over the years but is still 20% at one year 
after the procedure, as reported recently in the multicenter 
experience using CardioSeal and StarFlex devices13,15. With the 
Amplatzer occluder we observed a complete occlusion rate 
of 97-99% during follow up, with only 4 patients still showing 
a trivial shunt on color flow Doppler. Though these residual 
leaks are trivial, it seems of interest that with one exception 
they occurred only in patients who had an additional ASD or 
defects with an additional septal aneurysm.
Whether or not one should use general anesthesia for spe-
cific interventional procedures may be a question of economics 
for some institutions or simply a question of the availability 
of anesthetic coverage6,8,9,11,15. On the other hand, unlike adult 
patients, a child will not tolerate the TEE probe without heavy 
sedation (for example, with propofol or ketamine) and continued 
spontaneous breathing, which may carry a risk of air embolism 
through the long sheath, owing to the negative intrathoracic 
pressure. In order to avoid irreversible myocardial or cerebral 
damage or even death after air embolism to the left heart, we 
now perform all interventional ASD closures under general 
anesthesia with mechanical ventilation.
Until now, we have seen only one patient who developed 
arrhythmias after ASD closure with the Amplatzer occluder. In 
the case of a 38-year-old man with atrial flutter, development 
of the arrhythmia seemed to be the result of long standing 
right atrial volume overload and dilatation rather than being 
device related. In our patient group sudden onset of complete 
atrioventricular block did not occur.
c O N c L U s I O N s
Transcatheter closure of atrial septal defects has become a 
routine procedure in many countries of the world. It spares many 
patients cardiac surgery and has proven efficacy in long-term 
studies. Device improvements have resulted in a continuous 
reduction of complications and of residual shunt frequency. 
Although lifelong observation is required, this single center 
experience with the Amplatzer septal occluder shows good 
closure results for the majority of the ASD patients.
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ΕΠΙΣΗΜΑΝΣΗ
Η αναφορά των εικόνων στο κείμενο ξεκινά από την εικόνα 3 και η αναφορά των εικόνων 1, 2 και 
6 είναι μετά την αναφορά της εικόνας 8.
Μήπως θα ’πρεπε να αλλάξουμε την αρίθμηση των εικόνων και στις λεζάντες και στο κείμενο και 
να είναι τοποθετημένες οι εικόνες σύμφωνα με την αναφορά τους κείμενο;
Δηλαδή η αναφορά της εικόνας 3 στο κείμενο να γίνει 1 και η λεζάντα της εικόνας 3 να γίνει επίσης 
1 κ.λπ.
Ευχαριστώ.
